What is HC Wainwright’s Forecast for EBS Q1 Earnings?

Emergent BioSolutions Inc. (NYSE:EBS) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Emergent BioSolutions in a research note issued on Friday, March 21st. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will earn $0.87 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Emergent BioSolutions’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions’ Q2 2026 earnings at $1.04 EPS, Q3 2026 earnings at $1.11 EPS and Q4 2026 earnings at $0.81 EPS.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.40. The firm had revenue of $194.70 million for the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the firm earned ($0.77) EPS.

Separately, StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Stock Down 4.2 %

EBS stock opened at $5.49 on Monday. Emergent BioSolutions has a 1-year low of $1.82 and a 1-year high of $15.10. The stock has a market cap of $298.31 million, a P/E ratio of -1.34 and a beta of 1.80. The stock’s fifty day simple moving average is $8.33 and its two-hundred day simple moving average is $8.70. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EBS. Covestor Ltd grew its position in shares of Emergent BioSolutions by 5,458.5% in the fourth quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 2,893 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Emergent BioSolutions in the 4th quarter worth about $63,000. Stifel Financial Corp bought a new stake in shares of Emergent BioSolutions during the third quarter valued at about $96,000. E Fund Management Co. Ltd. purchased a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $98,000. Finally, FORA Capital LLC bought a new position in shares of Emergent BioSolutions in the third quarter valued at approximately $103,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now directly owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.